SINOTAU (09941.HK): Global Offering of 6.56m H Shares at Up to HK$68 Each
NewTimeSpace News: On 16 November 2026, Beijing Sinotau International Pharmaceutical Technology Co., Ltd. (stock code: 9941) published its global offering announcement for 6,561,000 H shares, subject to the over-allotment option, comprising 656,100 shares in the Hong Kong offer and 5,904,900 shares in the international offer, both subject to reallocation and representing about 10.0% and 90.0% of the offering.
The maximum offer price is HK$68.0 per H share, plus a 1% brokerage fee, a 0.0027% SFC transaction levy, a 0.00015% AFRC transaction levy and a 0.00565% Stock Exchange trading fee. The offer price is expected to be not less than HK$52.0 per share and will be determined later; the H shares have a nominal value of RMB1.00 each.
The Hong Kong public offer opened at 9:00 am on 16 November 2026, with electronic applications through the white form eIPO service closing at 11:30 am on 19 November 2026. The offering uses a fully electronic application process, no printed prospectus will be provided to the public, and the H shares will be issued in uncertificated form without physical certificates. After reallocation, the Hong Kong offer may rise to a maximum of 984,150 shares, about 15% of the offering.
Assuming the Hong Kong offer becomes unconditional by 8:00 am on 24 November 2026, trading in the H shares is expected to begin at 9:00 am the same day in board lots of 50 shares under stock code 9941. CICC Hong Kong Securities is the stabilising manager, with the stabilisation period expected to end on 19 December 2026.
- EDDING GENOR (06998.HK): GB268 Wins NMPA Nod for NSCLC, BTC Trials
- HENLIUS (02696.HK): NMPA Clears HLX105 Phase 1 Solid Tumour IND
- KLIGHT LASER: Closes New Round Led by China Fortune-Tech Capital, Expanding Deep-Ultraviolet Output
- OSMUNDA: Closes RMB 100 Million Series D Led Exclusively by Lishui Green Valley Talent Osmunda New Fund
- INNOVENT BIO (01801.HK): Sintilimab Gets First CHMP Positive Opinion for First-Line NSCLC